Cameron Durrant MD

CEO Humanigen

Dr. Durrant is an entrepreneur, board member, C-level executive, former big pharma executive and an MD by original training. He is Chairman and CEO of Humanigen, a Nasdaq-listed public company developing monoclonal antibodies for COVID-19, CAR-T, GvHD, oncology and other serious and life-threatening conditions. His specialty is both start-ups and turnarounds, including brands and business units as well as companies. He has served as board chairman, lead independent director and operated as CEO or interim CEO, as well as acting CFO and acting CMO for both private and public companies. He has been involved in 4 exits, including the $640MM acquisition of Hi-Tech Pharmacal by Akorn and the subsequent divestment of ECR Pharmaceuticals by Akorn to Valeant. He has raised several hundred million dollars from a variety of sources and has been an executive at several blue-chip big pharmacos and held business unit P+L and staff roles, both in the US and globally.